View Older Stories View More Recent Stories
-
Adcendo ApS Announces Extension of Series A Financing to EUR 98M to Further Bolster its First-in-Class ADC Pipeline
-
Be Biopharma Announces FDA Clearance of IND Application for BE-101 in Hemophilia B
-
Bicycle Therapeutics (BCYC) Announces $555 Million Private Placement Equity Financing
-
Bicycle Therapeutics Announces $555 Million Private Placement Equity Financing
-
Be Biopharma Expands Scientific Advisory Board with the Appointment of Cell and Gene Therapy Leader Dr. Paula Cannon
-
AltruBio Secures up to $225M Oversubscribed Series B Financing to Advance the Clinical Development of Novel Immune Checkpoint Enhancer Program
-
Form 13F-HR/A RA CAPITAL MANAGEMENT, For: Mar 31
-
Form SC 13D/A Eliem Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form 13F-HR RA CAPITAL MANAGEMENT, For: Mar 31
-
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
-
Form SC 13D/A iTeos Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Ajax Therapeutics Raises $95 Million Series C Financing To Advance First-in-Class Type II JAK2 Inhibitor, AJ1-11095, Into The Clinic
-
Form SC 13G Medicenna Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Be Biopharma Announces New Preclinical Data for Novel B Cell Medicine for the Potential Treatment of Hypophosphatasia
-
iTeos Therapeutics (ITOS) Announces $120 Million Registered Direct Offering
-
iTeos Therapeutics Announces $120 Million Registered Direct Offering
-
Form SC 13D/A Black Diamond Therapeuti Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates
-
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
-
Bluejay Therapeutics Secures $182 Million in Series C Financing to Propel Clinical Pipeline
-
Jnana Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
-
Form SC 13D/A Werewolf Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G Avidity Biosciences, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Sortera Technologies Announces Curt Sacks as Senior Vice President and CFO
-
Form SC 13G Zura Bio Ltd Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update
-
Mariana Oncology to be Acquired by Novartis (NVS) to Advance Precision Radiopharmaceuticals to Treat Cancer
-
Mariana Oncology to be Acquired by Novartis to Advance Precision Radiopharmaceuticals to Treat Cancer
-
Form SC 13D/A Aerovate Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Commons Clinic Invests $9.75M in Advanced Spine Surgery Center; Launches Next-Gen Ambulatory Surgical Platform "Theater"
-
Form SC 13G Protara Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million
-
Be Biopharma to Present at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
-
Zura Bio (ZURA) Enters $112.5M Private Placement
-
Zura Bio Announces Oversubscribed $112.5 Million Private Placement
-
Asher Bio Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical Trials
-
Form SC 13G Surrozen, Inc./DE Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D/A Eliem Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G Boundless Bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G CervoMed Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D/A Acrivon Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Eliem Therapeutics (ELYM) to Acquire Tenet Medicines, Announces Concurrent $120M Private Placement
-
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
-
TORL BioTherapeutics Announces $158 Million Oversubscribed Series B-2 Financing to Advance the Clinical Development of its Novel Antibody-Drug Conjugate (ADC) Oncology Pipeline
-
Acrivon Therapeutics (ACRV) Announces $130 Million Private Placement Financing
-
Acrivon Therapeutics Announces $130 Million Private Placement Financing
-
Adela Presents Data Demonstrating Ability of Tissue-Agnostic MRD Assay to Predict Recurrence in Head & Neck Cancer at the American Association for Cancer Research Annual Meeting 2024
-
Protara Therapeutics (TARA) Announces $45M Private Placement at $4.15/sh
-
Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing
-
Form SC 13G Dyne Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

